Athira Pharma Announces Board, Executive Changes & Compensation
Ticker: LONA · Form: 8-K · Filed: Oct 7, 2024 · CIK: 1620463
| Field | Detail |
|---|---|
| Company | Athira Pharma, INC. (LONA) |
| Form Type | 8-K |
| Filed Date | Oct 7, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $375,000, $363,750.00, $41,666.67, $0.4257 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, board-changes, employment-agreement
TL;DR
Athira Pharma shakes up board, inks new exec pay deals for CEO Gordon & CFO Shannon.
AI Summary
Athira Pharma, Inc. announced on October 1, 2024, changes in its board of directors and executive compensation. Dr. Hans-Ulrich Siehl has been appointed as a new director, and the company has entered into new employment agreements with its Chief Executive Officer, Mark L. Gordon, and Chief Financial Officer, R. Michael Shannon, effective October 1, 2024. These agreements outline their compensation and severance packages.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or leadership, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in executive leadership and board composition can introduce uncertainty regarding future strategy and operational execution.
Key Players & Entities
- Athira Pharma, Inc. (company) — Registrant
- Dr. Hans-Ulrich Siehl (person) — Appointed Director
- Mark L. Gordon (person) — Chief Executive Officer
- R. Michael Shannon (person) — Chief Financial Officer
- October 1, 2024 (date) — Effective date of changes
FAQ
Who has been appointed as a new director to Athira Pharma's board?
Dr. Hans-Ulrich Siehl has been appointed as a new director.
What is the effective date of the new employment agreements for the CEO and CFO?
The new employment agreements for the CEO and CFO are effective October 1, 2024.
Who are the key executives with new employment agreements?
Mark L. Gordon, the Chief Executive Officer, and R. Michael Shannon, the Chief Financial Officer, have new employment agreements.
What type of information is detailed in the new employment agreements?
The new employment agreements detail compensation and severance packages for the executives.
What is the former name of Athira Pharma, Inc.?
The former name of Athira Pharma, Inc. was M3 Biotechnology, Inc.
Filing Stats: 1,197 words · 5 min read · ~4 pages · Grade level 12.8 · Accepted 2024-10-07 16:05:08
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share ATHA The Nasdaq
- $375,000 — nation (representing a total payment of $375,000 to Ms. Lenington and a total payment of
- $363,750.00 — to Ms. Lenington and a total payment of $363,750.00 to Mr. Gengos) and (2) Company payment
- $41,666.67 — s an independent contractor and receive $41,666.67 per full calendar month, prorated for a
- $0.4257 — t value per share on the date of grant ($0.4257 per share for Dr. Litton and $0.4499 pe
- $0.4499 — t ($0.4257 per share for Dr. Litton and $0.4499 per share for Mr. Renninger) (each, an
Filing Documents
- atha-20241001.htm (8-K) — 55KB
- atha-ex10_1.htm (EX-10.1) — 104KB
- atha-ex10_2.htm (EX-10.2) — 223KB
- img61222073_0.jpg (GRAPHIC) — 809KB
- 0000950170-24-113210.txt ( ) — 1676KB
- atha-20241001.xsd (EX-101.SCH) — 26KB
- atha-20241001_htm.xml (XML) — 5KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1* Separation Agreement and Release between Andrew Gengos and Athira Pharma, Inc. dated October 3, 2024 10.2* Separation Agreement and Release between Rachel Lenington and Athira Pharma, Inc. dated October 1, 2024 104 Cover Page Interactive Data File (formatted as Inline XBRL) * Certain portions of this exhibit have been omitted because they are not material and is the type of information that the company treats as private or confidential.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Athira Pharma, Inc. Date: October 7, 2024 By: /s/ Mark Litton Mark Litton President and Chief Executive Officer